Timoptic

Generic Name: Timoptic

What is Timoptic?

Rivaroxaban: Avoid concurrent administration of platelet inhibitors such as clopidogrel with rivaroxaban unless the benefit outweighs the risk of increased bleeding. An increase in bleeding time to 45 minutes was observed in two drug interaction studies where clopidogrel 300 mg loading dose followed by 75 mg daily maintenance dose and rivaroxaban 15 mg single dose were coadministered in healthy subjects.

The change in bleeding time was approximately twice the maximum increase seen with either drug alone. No change in the pharmacokinetic parameters of either drug were noted. Sertraline: Platelet aggregation may be impaired by selective serotonin reuptake inhibitors SSRIs due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e. Sodium Bicarbonate: Administration of ticlopidine after antacids results in a decrease in plasma levels of ticlopidine.

Sodium Hyaluronate, Hyaluronic Acid: Increased bruising or bleeding at the injection site may occur when using hyaluronate sodium with platelet inhibitors especially if used within the 3 weeks prior to the procedure. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events.

Sorafenib: Due to the thrombocytopenic effects of sorafenib, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors. Sulfinpyrazone: Sulfinpyrazone, when used as a uricosuric agent should be avoided when possible with concurrent platelet inhibitors due to potential for additive antiplatelet effects and increased bleeding risk.

Tamoxifen: Ticlopidine is a CYP2C19 inhibitor.

If detected, neutropenia and thrombocytopenia can almost always be reversed. It is essential that you keep your appointments for the blood tests and that you call your doctor immediately if you have any indication that you may have TTP or neutropenia. If you stop taking TICLID ticlopidine hcl for any reason within the first 3 months, you will still need to have your blood tested for an additional 2 weeks after you have stopped taking TICLID ticlopidine hcl.

Rarely, decreases in the white blood cells, red blood cells and platelets can occur together. This condition is called aplastic anemia and can be fatal. Things you should watch for as possible early signs of aplastic anemia are feeling of excessive weakness and tiredness, paleness, bruising, and bleeding from areas such as your nose or gums.

You may also develop signs of infection such as fever. Other Warnings and Precautions: A few people may develop jaundice while being treated with TICLID ticlopidine hcl. The signs of jaundice are yellowing of the skin or the whites of the eyes or consistent darkening of the urine or lightening in the color of the stools.

These symptoms should be reported to your physician promptly. If any of the symptoms described above for neutropenia, TTP, aplastic anemia or jaundice occur, contact your doctor immediately.

TICLID ticlopidine hcl should be used only as directed by your doctor. Do not give TICLID ticlopidine hcl to anyone else. Keep TICLID ticlopidine hcl out of reach of children.

Some people may have such side effects as diarrhea, skin rash, stomach or intestinal discomfort.

How should I take Timoptic?

However, on the basis of the randomized and registry data and indirect data summarized above, it seems that clopidogrel is at least as efficacious as ticlopidine at preventing stent thrombosis and other adverse ischemic events, and has fewer side effects. Therefore, when considering the risk:benefit ratio of switching from ticlopidine to clopidogrel after stent placement, the driving force is clearly that there is less risk with clopidogrel, rather than a greater benefit with clopidogrel.

Whether clopidogrel does provide greater benefit than ticlopidine remains to be proved. Despite TOPPS, several important questions remain unanswered about the use of clopidogrel after stent placement.

Whether the more rapid achievement of platelet inhibition achieved by such large loading doses will improve clinical outcome is unknown. Peak inhibition of platelet aggregation with even a 300 mg loading dose will still be reached during the infusion of such agents.

What should I avoid while taking Timoptic?

If these drugs are used together, monitor for loperamide-associated adverse reactions, such as CNS effects and cardiac toxicities i. Mercaptopurine, 6-MP: Due to the thrombocytopenic effects of purine analogs, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors.

Methoxsalen: Agents that affect platelet function, such as platelet inhibitors, could decrease the efficacy of methoxsalen when used during photodynamic therapy. Methylsulfonylmethane, MSM: Increased effects from concomitant anticoagulant drugs including increased bruising or blood in the stool have been reported in patients taking methylsulfonylmethane, MSM.

Milnacipran: Platelet aggregation may be impaired by serotonin norepinephrine reuptake inhibitors SNRIs due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Timoptic side effects

One episode of ecchymosis was reported, but no major bleeding episodes occurred. The authors concluded that fish oil supplementation in doses of 36 grams per day does not have a statistically significant effect on the INR of patients receiving chronic warfarin therapy. However, an increase in INR from 2.

This implies that a dose-related effect of fish oil on warfarin may be possible. Patients receiving warfarin that initiate concomitant icosapent ethyl therapy should have their INR monitored more closely and the dose of warfarin adjusted accordingly. Ifosfamide: An additive risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia including antineoplastic agents, such as ifosfamide.

Common Timoptic ide effects may include:

  • Ticlopidine hydrochloride, after oral ingestion, interferes with platelet membrane function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-platelet interactions.

  • Common side effects of platelet inhibitors include headache, dizziness, and vomiting.

  • Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.

  • Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs.

Who Should Not Take TICLID ticlopidine hcl. Contact your doctor immediately and do not take TICLID ticlopidine hcl if: you have an allergic reaction to TICLID ticlopidine hcl you have a blood disorder or a serious bleeding problem, such as a bleeding stomach ulcer you have previously been told you had TTP or aplastic anemia you have severe liver disease or other liver problems you are pregnant or you are planning to become pregnant you are breast-feeding Pill Identifier Tool Quick, Easy, Pill Identification Drug Interaction Tool Check Potential Drug Interactions Pharmacy Locater Tool Including 24 Hour, Pharmacies Ticlid Drug Imprint Ticlid 250 mg Related Drugs Angiomax Argatroban Bivalirudin Plavix Vasovist Health Resources Peripheral Vascular Disease Stroke Signs, Symptoms, Warning Signs Chest Diabetes and You Online Hearing Test Managing Diabetes Expert Orthopedic Care Monitor Glucose Spikes Treat Pet Anxiety Advanced Breast Cancer Care for Valve Disease.

Ticlopidine trade name Ticlid is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate ADP receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions.

Where can I get more information?

  • How should I take ticlopidine Ticlid.

  • The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else.